NewAmsterdam Pharma Warrant
NAMSW
18 hedge funds and large institutions have $5M invested in NewAmsterdam Pharma Warrant in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 4 reducing their positions, and 5 closing their positions.
10% more capital invested
Capital invested by funds: $4.53M → $5M (+$471K)
14% less funds holding
Funds holding: 21 → 18 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$58.7K |
| 2 |
CS
Clear Street
New York
|
+$28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.89M |
| 2 |
ETH
Exos TFP Holdings
New York
|
-$68.8K |
| 3 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
-$43K |
| 4 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$36.5K |
| 5 |
DCM
Dupont Capital Management
Wilmington,
Delaware
|
-$6.67K |
NAMSW Hedge Fund Activity: Q1 2023 in Review
18 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q1 2023, worth a combined $5M — up 10% from $4.53M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NAMSW and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 0 added.
The largest buyer was Affinity Asset Advisors, opening a new position worth an estimated $58.7K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.89M sold.
- 18 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q1 2023, down from 21 in Q4 2022.
- Funds reported $5M of NewAmsterdam Pharma Warrant stock for Q1 2023, up 10% quarter-over-quarter.
- 2 funds opened new NewAmsterdam Pharma Warrant positions in Q1 2023 and 5 closed out, a net change of -3 holders.
- The largest NewAmsterdam Pharma Warrant buyer in Q1 2023 was Affinity Asset Advisors, an estimated $58.7K added.
- The largest NewAmsterdam Pharma Warrant seller in Q1 2023 was Alyeska Investment Group, an estimated $1.89M sold.
Based on aggregated 13F filings for Q1 2023.